|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SP2 |
Gene summary for SP2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SP2 | Gene ID | 6668 |
| Gene name | Sp2 transcription factor | |
| Gene Alias | SP2 | |
| Cytomap | 17q21.32 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q02086 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6668 | SP2 | LZE4T | Human | Esophagus | ESCC | 8.55e-09 | 1.70e-01 | 0.0811 |
| 6668 | SP2 | LZE8T | Human | Esophagus | ESCC | 3.33e-02 | 8.88e-02 | 0.067 |
| 6668 | SP2 | LZE24T | Human | Esophagus | ESCC | 1.83e-09 | 2.13e-01 | 0.0596 |
| 6668 | SP2 | LZE21T | Human | Esophagus | ESCC | 2.46e-05 | 2.67e-01 | 0.0655 |
| 6668 | SP2 | P1T-E | Human | Esophagus | ESCC | 1.11e-05 | 3.33e-01 | 0.0875 |
| 6668 | SP2 | P2T-E | Human | Esophagus | ESCC | 5.79e-19 | 2.59e-01 | 0.1177 |
| 6668 | SP2 | P4T-E | Human | Esophagus | ESCC | 5.86e-08 | 1.77e-01 | 0.1323 |
| 6668 | SP2 | P5T-E | Human | Esophagus | ESCC | 7.06e-09 | 6.78e-02 | 0.1327 |
| 6668 | SP2 | P8T-E | Human | Esophagus | ESCC | 1.21e-15 | 3.35e-01 | 0.0889 |
| 6668 | SP2 | P9T-E | Human | Esophagus | ESCC | 1.76e-04 | 1.10e-01 | 0.1131 |
| 6668 | SP2 | P10T-E | Human | Esophagus | ESCC | 2.19e-18 | 2.01e-01 | 0.116 |
| 6668 | SP2 | P11T-E | Human | Esophagus | ESCC | 2.16e-06 | 3.30e-01 | 0.1426 |
| 6668 | SP2 | P12T-E | Human | Esophagus | ESCC | 1.08e-18 | 2.80e-01 | 0.1122 |
| 6668 | SP2 | P15T-E | Human | Esophagus | ESCC | 3.46e-10 | 2.25e-01 | 0.1149 |
| 6668 | SP2 | P16T-E | Human | Esophagus | ESCC | 4.54e-16 | 2.13e-01 | 0.1153 |
| 6668 | SP2 | P17T-E | Human | Esophagus | ESCC | 1.65e-05 | 2.06e-01 | 0.1278 |
| 6668 | SP2 | P19T-E | Human | Esophagus | ESCC | 3.63e-04 | 2.50e-01 | 0.1662 |
| 6668 | SP2 | P20T-E | Human | Esophagus | ESCC | 8.04e-15 | 2.29e-01 | 0.1124 |
| 6668 | SP2 | P21T-E | Human | Esophagus | ESCC | 3.45e-11 | 2.12e-01 | 0.1617 |
| 6668 | SP2 | P22T-E | Human | Esophagus | ESCC | 5.57e-10 | 1.33e-01 | 0.1236 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190589712 | Liver | HCC | regulation of response to endoplasmic reticulum stress | 62/7958 | 82/18723 | 1.06e-09 | 3.23e-08 | 62 |
| GO:00165732 | Liver | HCC | histone acetylation | 101/7958 | 152/18723 | 1.99e-09 | 5.63e-08 | 101 |
| GO:00447722 | Liver | HCC | mitotic cell cycle phase transition | 240/7958 | 424/18723 | 2.47e-09 | 6.84e-08 | 240 |
| GO:007138322 | Liver | HCC | cellular response to steroid hormone stimulus | 128/7958 | 204/18723 | 3.92e-09 | 1.04e-07 | 128 |
| GO:000734611 | Liver | HCC | regulation of mitotic cell cycle | 255/7958 | 457/18723 | 4.96e-09 | 1.30e-07 | 255 |
| GO:003367322 | Liver | HCC | negative regulation of kinase activity | 144/7958 | 237/18723 | 9.76e-09 | 2.45e-07 | 144 |
| GO:000193322 | Liver | HCC | negative regulation of protein phosphorylation | 196/7958 | 342/18723 | 1.95e-08 | 4.63e-07 | 196 |
| GO:00439671 | Liver | HCC | histone H4 acetylation | 50/7958 | 67/18723 | 9.14e-08 | 1.82e-06 | 50 |
| GO:001631121 | Liver | HCC | dephosphorylation | 230/7958 | 417/18723 | 1.00e-07 | 1.96e-06 | 230 |
| GO:015011522 | Liver | HCC | cell-substrate junction organization | 69/7958 | 101/18723 | 1.36e-07 | 2.57e-06 | 69 |
| GO:00070302 | Liver | HCC | Golgi organization | 99/7958 | 157/18723 | 1.54e-07 | 2.85e-06 | 99 |
| GO:000647021 | Liver | HCC | protein dephosphorylation | 162/7958 | 281/18723 | 1.91e-07 | 3.46e-06 | 162 |
| GO:00165742 | Liver | HCC | histone ubiquitination | 37/7958 | 47/18723 | 4.37e-07 | 7.23e-06 | 37 |
| GO:000646912 | Liver | HCC | negative regulation of protein kinase activity | 126/7958 | 212/18723 | 4.55e-07 | 7.49e-06 | 126 |
| GO:190357312 | Liver | HCC | negative regulation of response to endoplasmic reticulum stress | 35/7958 | 44/18723 | 5.70e-07 | 9.03e-06 | 35 |
| GO:000704422 | Liver | HCC | cell-substrate junction assembly | 64/7958 | 95/18723 | 8.33e-07 | 1.28e-05 | 64 |
| GO:19019901 | Liver | HCC | regulation of mitotic cell cycle phase transition | 167/7958 | 299/18723 | 1.96e-06 | 2.71e-05 | 167 |
| GO:19019871 | Liver | HCC | regulation of cell cycle phase transition | 211/7958 | 390/18723 | 2.11e-06 | 2.89e-05 | 211 |
| GO:007084911 | Liver | HCC | response to epidermal growth factor | 37/7958 | 49/18723 | 2.70e-06 | 3.61e-05 | 37 |
| GO:004340121 | Liver | HCC | steroid hormone mediated signaling pathway | 84/7958 | 136/18723 | 4.42e-06 | 5.62e-05 | 84 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| SP2 | DIF | Skin | cSCC | MT1M,NOS1AP,TBC1D31, etc. | 3.96e-01 |  |
| SP2 | GC | Stomach | CAG | ZNRD1,AC010642.1,RAB3IP, etc. | 1.76e-02 |  |
| SP2 | BMEM | Stomach | Healthy | ZNRD1,AC010642.1,RAB3IP, etc. | 1.22e-02 |  |
| SP2 | TREG | Stomach | SIM | ZNRD1,AC010642.1,RAB3IP, etc. | 6.08e-02 |  |
| SP2 | BN | Stomach | SIM | ZNRD1,AC010642.1,RAB3IP, etc. | 2.22e-02 | |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SP2 | SNV | Missense_Mutation | c.1657C>T | p.Arg553Trp | p.R553W | Q02086 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | SD | ||
| SP2 | SNV | Missense_Mutation | novel | c.1277N>T | p.Ala426Val | p.A426V | Q02086 | protein_coding | deleterious(0.03) | benign(0.039) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SP2 | SNV | Missense_Mutation | novel | c.1249N>T | p.Pro417Ser | p.P417S | Q02086 | protein_coding | deleterious(0.02) | benign(0.355) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| SP2 | deletion | Frame_Shift_Del | novel | c.831delN | p.Ile278SerfsTer117 | p.I278Sfs*117 | Q02086 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| SP2 | deletion | Frame_Shift_Del | c.1113delN | p.Pro373GlnfsTer22 | p.P373Qfs*22 | Q02086 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |||
| SP2 | SNV | Missense_Mutation | c.787G>A | p.Glu263Lys | p.E263K | Q02086 | protein_coding | deleterious(0.05) | possibly_damaging(0.551) | TCGA-EK-A3GJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| SP2 | SNV | Missense_Mutation | c.1504N>T | p.Arg502Cys | p.R502C | Q02086 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SP2 | SNV | Missense_Mutation | novel | c.1738N>G | p.Thr580Ala | p.T580A | Q02086 | protein_coding | deleterious(0) | possibly_damaging(0.602) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| SP2 | SNV | Missense_Mutation | c.529G>A | p.Val177Ile | p.V177I | Q02086 | protein_coding | tolerated(0.06) | possibly_damaging(0.69) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SP2 | SNV | Missense_Mutation | c.401C>T | p.Ala134Val | p.A134V | Q02086 | protein_coding | tolerated(1) | benign(0.001) | TCGA-D5-6540-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |